Collegium Pharmaceutical Inc - Kewajiban jangka dawa perusahaan COLL

Collegium Pharmaceutical (COLL) focuses on the therapy of severe pain syndromes, capturing a massive US opioid segment by developing safe drug formulations. Despite patent protection, pricing power is constrained by insurance company requirements. The price action of specific long-term debt is 1.09, while the business generates revenue from supplying prescription medications to pharmacy chains and specialized medical centers.

Fundamental stock selection requires an analysis of the liability structure to assess business resilience to borrowing costs. This indicator captures the volume of credit obligations with a maturity of over one year, which on the GURU.Markets platform, via the issuer's long-term liabilities, allows for an assessment of the ability of Collegium Pharmaceutical (COLL) to finance its defensive analgesic ecosystem without a critical debt load.